The US FDA has granted ODD to NT-I7 & bolsters NeoImmuneTech’s determination to advance the clinical development of NT-I7 as new therapy for Glioblastoma Multiforme
In the P-I & II trial, NT-I7 showed promise for expanding T cells in all subsets, enhancing the immune system, and extending the anti-tumor response in patients with GBM and other solid tumors while the preliminary data from (the NIT-107) study showed favorable trends of PFS and OS in NT-I7 treated HGG patients after chemoradiotherapy
NT-I7 is being evaluated in multiple trials for solid tumors and as a vaccine adjuvant. Additionally, studies in additional solid tumors, hematologic malignancies, and other immunology-related indications are being planned
Ref: PRNewswire | Image: NeoImmuneTech
